Celularity vs Lenz Therapeutics
Celularity is the larger business, with $26.6m of revenue in fiscal 2025 against $19.1m for Lenz Therapeutics (1.4 times as much). Celularity kept more of each dollar of sales as profit: a net margin of -345.4% against -430.3%.
| Latest fiscal year | CelularityCELU, 2025 | Lenz TherapeuticsLENZ, 2025 |
|---|---|---|
| Revenue | $26.6m | $19.1m |
| Revenue growth | -51.0% | — |
| Net income | −$91.7m | −$82.1m |
| Operating margin | -230.9% | -477.5% |
| Net margin | -345.4% | -430.3% |
| Return on equity | — | -33.6% |
| Free cash flow | −$13.3m | −$70.0m |
| Cash | $6.2m | $25.2m |
| Total debt | $33.8m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 115 | 152 |
| Market value | $24.0m | $111m |
| Price vs our value range | — | — |
| Moat score | 18 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 6 buys, 5 sales |